Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chitosan and milk thistle

This article was originally published in The Tan Sheet

Executive Summary

National Toxicology Program's Board of Scientific Counselors approves chitosan for testing to determine whether it blocks the absorption of dietary fat and depletes the body of vitamin E and other minerals at a May 24 meeting. NIH's National Cancer Institute nominated the substance and NTP's Interagency Committee for Chemical Evaluation & Coordination recommended it for testing. The decision now moves to NTP's Executive Committee, which will meet in late June. NTP also notes sub-chronic and chronic studies of milk thistle have been developed and are awaiting approval; ICCEC recommended last July that toxicity testing be conducted on the botanical along with aloe vera, ginseng and kava kava (1"The Tan Sheet" Aug. 2, 1999, p. 3)

You may also be interested in...



Aloe, Ginseng, Kava, Milk Thistle Recommended For NTP Toxicology Testing

The National Toxicology Program Interagency Committee for Chemical Evaluation and Coordination (ICCEC) has recommended possible toxicity testing for the botanicals aloe vera, ginseng, kava kava and milk thistle. Nomination of the four plant substances was announced July 27 by the National Institute of Environmental Health Sciences. Scientific information and public comments will be accepted through Sept. 7.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel